THE SCIENCE
Daily Peanuts Changed How Older Brains Responded to a Nasal Insulin Spray. Nobody Knows Yet What That Means
Insulin is usually discussed as a pancreas-and-liver hormone, the 51-amino-acid peptide that helps regulate blood sugar. But the brain responds to insulin too, and...
THE SCIENCE
More Than Half Reached Type 2 Diabetes Remission With Diet and Exercise. The Trial Lasted Six Months.
In an era when the answer to almost every metabolic question seems to arrive in a weekly injection pen, a randomized trial of younger...
THE SCIENCE
Men on GLP-1 Drugs Had Better Sperm a Year Later. The Study Can’t Say the Drugs Did It
Most of the questions people ask about Ozempic and fertility concern women: whether the medicines affect contraception, how long to stop before pregnancy, and...
THE SCIENCE
A Fatty Acid Killed “Zombie” Cells in the Lab. Don’t Reach for Supplements Yet.
Senescent cells are often nicknamed "zombie" cells.
They have stopped dividing but remain alive, sometimes lingering in aging tissues and releasing inflammatory signals that can...
THE SCIENCE
Lilly’s Obesity Pill Cleared a Japanese Phase 3. The Highest Dose Didn’t Lose the Most Weight.
Eli Lilly's oral obesity drug orforglipron, sold in the United States as Foundayo, has now produced positive results in a 72-week Phase 3 clinical...
THE SCIENCE
Novo Will Put Wegovy Beside Rezdiffra at the Liver Meeting. It Isn’t a Head-to-Head Trial.
Rezdiffra and Wegovy are both FDA-approved for certain adults with metabolic dysfunction-associated steatohepatitis, or MASH, and moderate to advanced liver scarring. Now researchers are...
THE SCIENCE
Novo Will Put Wegovy Beside Rezdiffra at the Liver Meeting. It Isn’t a Head-to-Head Trial.
Two drugs are now FDA-approved for a defined form of fatty liver disease with significant scarring. One targets metabolic pathways throughout the body. The...
THE SCIENCE
Lilly’s Obesity Pill Cleared a Japanese Phase 3. The Highest Dose Didn’t Lose the Most Weight.
Eli Lilly's oral obesity drug orforglipron, sold in the United States as Foundayo, has now passed a 72-week Phase 3 trial in Japan.
All three...
